1000277-08-6
Chemical Structure
MGB-BP-3
- CAS No.: 1000277-08-6
- Formula:C36H37N7O4
- Molecular Weight:631.72
IUPAC Name: (E)-1-methyl-4-(1-methyl-4-(4-(2-(quinolin-3-yl)vinyl)benzamido)-1H-pyrrole-2-carboxamido)-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide
InChIKey: OEKXCVYZBVOWBR-BQYQJAHWSA-N
SMILES: O=C(C1=CC(NC(C2=CC=C(/C=C/C3=CC4=CC=CC=C4N=C3)C=C2)=O)=CN1C)NC5=CN(C)C(C(NCCN6CCOCC6)=O)=C5
Biological Activity: MGB-BP-3 is an orally aective Gram-positive bactericide and DNA-binding agent. MGB-BP-3 blocks transcription initiation by binding to AT-rich bacterial DNA regions, and interferes with the functions of DNA gyrase and topoisomerase IV, but does not stabilize cleavage complexes or induce the SOS response. MGB-BP-3 induces energy depletion in *Staphylococcus aureus* and inhibits spore formation in *Clostridioides difficile*, exhibiting intrinsic resistance resilience. MGB-BP-3 can be used in the research of *Clostridioides difficile*-associated diseases[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MGB-BP-3 | 99.85% | MGB-BP-3 is an orally aective Gram-positive bactericide and DNA-binding agent. MGB-BP-3 blocks transcription initiation by binding to AT-rich bacterial DNA regions, and interferes with the functions of DNA gyrase and topoisomerase IV, but does not stabilize cleavage complexes or induce the SOS response. MGB-BP-3 induces energy depletion in *Staphylococcus aureus* and inhibits spore formation in *Clostridioides difficile*, exhibiting intrinsic resistance resilience. MGB-BP-3 can be used in the research of *Clostridioides difficile*-associated diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MGB-BP-3 (Standard) | ≥98% | MGB-BP-3 (Standard) is the analytical standard of MGB-BP-3 (HY-U00035). This product is intended for research and analytical applications. MGB-BP-3 is an orally aective Gram-positive bactericide and DNA-binding agent. MGB-BP-3 blocks transcription initiation by binding to AT-rich bacterial DNA regions, and interferes with the functions of DNA gyrase and topoisomerase IV, but does not stabilize cleavage complexes or induce the SOS response. MGB-BP-3 induces energy depletion in *Staphylococcus aureus* and inhibits spore formation in *Clostridioides difficile*, exhibiting intrinsic resistance resilience. MGB-BP-3 can be used in the research of *Clostridioides difficile*-associated diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hind C, et al. Insights into the Spectrum of Activity and Mechanism of Action of MGB-BP-3. ACS infectious diseases. 2022 Dec 09;8(12):2552-2563. [Content Brief]
- [2]. Suckling CJ, et al. Multitargeted anti-infective drugs: resilience to resistance in the antimicrobial resistance era. Future drug discovery. 2022 Apr;4(1):FDD73. [Content Brief]
- [3]. Alshrari A S, et al. The urgent threat of Clostridioides difficile infection: A glimpse of the drugs of the future, with related patents and prospects[J]. Biomedicines, 2023, 11(2): 426.
